Abstract
This review gives an overview of recent advances in our understanding of the molecular basis of gynaecological malignancy, including cervical, vulval, endometrial and ovarian tumours. These advances are beginning to influence clinical practice, perhaps most notably with the introduction of human papillomavirus vaccination for the prevention of anogenital neoplasia, but are likely to have broader clinical implications as further details emerge.
Original language | English |
---|---|
Pages (from-to) | 243-249 |
Number of pages | 7 |
Journal | Histopathology |
Volume | 55 |
Issue number | 3 |
DOIs | |
Publication status | Published - Sept 2009 |
Keywords
- cervix
- endometrium
- gynaecology
- molecular
- ovary
- pathology
- vulva
- VULVAR INTRAEPITHELIAL NEOPLASIA
- HUMAN-PAPILLOMAVIRUS TYPE-16
- SQUAMOUS-CELL CARCINOMA
- RANDOMIZED CONTROLLED-TRIAL
- PARTICLE VACCINE
- SEROUS CARCINOMA
- MICROSATELLITE INSTABILITY
- ENDOMETRIAL CARCINOMA
- LOW-GRADE
- CERVICAL CARCINOGENESIS